EVALUATION OF PLATELET RESPONSE TO DIFFERENT CLOPIDOGREL DOSING REGIMENS IN PATIENTS WITH ACUTE CORONARY SYNDROME IN CLINICAL PRACTICE  by Fefer, Paul et al.
E484
JACC March 27, 2012
Volume 59, Issue 13
Acute Coronary Syndromes 
EVALUATION OF PLATELET RESPONSE TO DIFFERENT CLOPIDOGREL DOSING REGIMENS IN PATIENTS 
WITH ACUTE CORONARY SYNDROME IN CLINICAL PRACTICE
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Sunday, March 25, 2012, 11:00 a.m.-Noon
Session Title: Acute Coronary Syndromes: Therapy V
Abstract Category: 4. Acute Coronary Syndromes: Therapy
Presentation Number: 1160-630
Authors: Paul Fefer, Roy Beigel, Boris Shenkman, Sharon Gannot, David Varon, Naphthali Savion, Hanoch Hod, Shlomi Matetzky, Sheba Medical 
Center, Tel Aviv, Israel, Hadassah Hebrew University, Jerusalem, Israel
Background: The optimal dose of clopidogrel has been the subject of much debate. The CURRENT-OASIS 7 study found that administration of 
high clopidogrel loading and maintenance doses in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention 
(PCI) resulted in significantly better outcomes, however platelet responsiveness was not assessed. We report on platelet function in similar patients 
treated with different clopidogerel doses.
Methods: We prospectively evaluated 402 consecutive ACS patients admitted to the cardiac intensive care unit. Three clopidogrel dosing regimens 
were evaluated: 300 mg loading and 75 mg/day maintenance (n=198); 600 mg loading and 75 mg/day maintenance (n=94); and 600 mg loading 
and 75 mg/day maintenance for 7 days (n=110). Platelet reactivity was assessed by light transmission aggregometry on day 3.
Results: Average age was 60±12 years, 82% of patients were male, 22% had diabetes, 43% were smokers, and 75% presented with ST-elevation 
ACS. No major differences were noted in baseline, angiographic, or laboratory data between groups. Progressively greater inhibition of platelet 
aggregation was observed over the 3 dosing regimens (see figure).
Conclusion: In ACS patients, greater platelet inhibition can be achieved with higher clopidogrel loading and maintenance doses. This finding is 
likely responsible for the reduced atherothrombotic complications, including less stent thrombosis, reported in the CURRENT-OASIS 7 PCI substudy.
 
